1. Home
  2. GIPR vs LYRA Comparison

GIPR vs LYRA Comparison

Compare GIPR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Income Properties Inc.

GIPR

Generation Income Properties Inc.

HOLD

Current Price

$0.75

Market Cap

6.4M

Sector

Real Estate

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$2.32

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIPR
LYRA
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.6M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
GIPR
LYRA
Price
$0.75
$2.32
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
68.0K
120.1K
Earning Date
11-17-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,953,920.00
$600,000.00
Revenue This Year
$1.12
N/A
Revenue Next Year
$0.52
$93.90
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.63
52 Week High
$2.06
$37.50

Technical Indicators

Market Signals
Indicator
GIPR
LYRA
Relative Strength Index (RSI) 44.99 34.63
Support Level $0.71 $1.63
Resistance Level $0.86 $2.58
Average True Range (ATR) 0.06 0.27
MACD 0.01 -0.08
Stochastic Oscillator 47.76 25.54

Price Performance

Historical Comparison
GIPR
LYRA

About GIPR Generation Income Properties Inc.

Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: